Bookmark
Forward
QuickView for Nitric oxide (compound)
PubChem
| Name: | Nitric Oxide |
|---|---|
| PubChem Compound ID: | 140063 |
| Description: | A free radical gas produced endogenously by a variety of mammalian cells, synthesized from ARGININE by NITRIC OXIDE SYNTHASE. Nitric oxide is one of the ENDOTHELIUM-DEPENDENT RELAXING FACTORS released by the vascular endothelium and mediates VASODILATION. It also inhibits platelet aggregation, induces disaggregation of aggregated platelets, and inhibits platelet adhesion to the vascular endothelium. Nitric oxide activates cytosolic GUANYLATE CYCLASE and thus elevates intracellular levels of CYCLIC GMP. |
| Molecular formula: | HNO |
| Molecular weight: | 32.0202 g/mol |
| Synonyms: |
16355-69-4; Nitrosyl hydride-d1; DNO; Nitrosyl hydride, d1
|
DrugBank
Identification
| Name: | Nitric Oxide |
|---|---|
| Name (isomeric): | DB00435 |
| Drug Type: | small molecule |
| Description: | A free radical gas produced endogenously by a variety of mammalian cells, synthesized from ARGININE by NITRIC OXIDE SYNTHASE. Nitric oxide is one of the ENDOTHELIUM-DEPENDENT RELAXING FACTORS released by the vascular endothelium and mediates VASODILATION. It also inhibits platelet aggregation, induces disaggregation of aggregated platelets, and inhibits platelet adhesion to the vascular endothelium. Nitric oxide activates cytosolic GUANYLATE CYCLASE and thus elevates intracellular levels of CYCLIC GMP. |
| Brand: | Nitrogen monoxide, Nitrosyl radical, Mononitrogen monoxide, NO, Amidogen, oxo-, INOmax, nitrogen protoxide, Nitric oxide trimer, Nitric oxide 10% by volume or more, Nitrogen monooxide, NMO, RCRA waste number P076, Nitrogen oxide |
| Category: | Free Radical Scavengers, Endothelium-Dependent Relaxing Factors, Bronchodilator Agents |
| CAS number: | 10102-43-9 |
Pharmacology
| Indication: | For the treatment of term and near-term (>34 weeks) neonates with hypoxic respiratory failure |
|---|---|
| Pharmacology: |
Persistent pulmonary hypertension of the newborn (PPHN) occurs as a primary developmental defect or as a condition secondary to other diseases such as meconium aspiration syndrome (MAS), pneumonia, sepsis, hyaline membrane disease, congenital diaphragmatic hernia (CDH), and pulmonary hypoplasia. In these states, pulmonary vascular resistance (PVR) ...
show more » |
| Mechanism of Action: |
Nitric oxide is a compound produced by many cells of the body. It relaxes vascular smooth muscle by binding to the heme moiety of cytosolic guanylate cyclase, activating guanylate cyclase and increasing intracellular levels of cyclic guanosine 3',5'-monophosphate, which then leads to vasodilation. When inhaled, nitric oxide produces pulmonary vasod...
show more » |
| Absorption: | Nitric oxide is absorbed systemically after inhalation. |
| Biotransformation: | via pulmonary capillary bed |
| Route of elimination: | Nitrate has been identified as the predominant nitric oxide metabolite excreted in the urine, accounting for >70% of the nitric oxide dose inhaled. |
| Half Life: | 2–6 seconds |
| Affected organisms: | Humans and other mammals |
Targets
